Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2010

Open Access 01-12-2010 | Research

Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine

Authors: Amed Ouattara, Jianbing Mu, Shannon Takala-Harrison, Renion Saye, Issaka Sagara, Alassane Dicko, Amadou Niangaly, Junhui Duan, Ruth D Ellis, Louis H Miller, Xin-zhuan Su, Christopher V Plowe, Ogobara K Doumbo

Published in: Malaria Journal | Issue 1/2010

Login to get access

Abstract

Background

Extensive genetic diversity in vaccine antigens may contribute to the lack of efficacy of blood stage malaria vaccines. Apical membrane antigen-1 (AMA1) is a leading blood stage malaria vaccine candidate with extreme diversity, potentially limiting its efficacy against infection and disease caused by Plasmodium falciparum parasites with diverse forms of AMA1.

Methods

Three hundred Malian children participated in a Phase 2 clinical trial of a bivalent malaria vaccine that found no protective efficacy. The vaccine consists of recombinant AMA1 based on the 3D7 and FVO strains of P. falciparum adjuvanted with aluminum hydroxide (AMA1-C1). The gene encoding AMA1 was sequenced from P. falciparum infections experienced before and after immunization with the study vaccine or a control vaccine. Sequences of ama1 from infections in the malaria vaccine and control groups were compared with regard to similarity to the vaccine antigens using several measures of genetic diversity. Time to infection with parasites carrying AMA1 haplotypes similar to the vaccine strains with respect to immunologically important polymorphisms and the risk of infection with vaccine strain haplotypes were compared.

Results

Based on 62 polymorphic AMA1 residues, 186 unique ama1 haplotypes were identified among 315 ama1 sequences that were included in the analysis. Eight infections had ama1 sequences identical to 3D7 while none were identical to FVO. Several measures of genetic diversity showed that ama1 sequences in the malaria vaccine and control groups were comparable both at baseline and during follow up period. Pre- and post-immunization ama1 sequences in both groups all had a similar degree of genetic distance from FVO and 3D7 ama1. No differences were found in the time of first clinical episode or risk of infection with an AMA1 haplotype similar to 3D7 or FVO with respect to a limited set of immunologically important polymorphisms found in the cluster 1 loop of domain I of AMA1.

Conclusion

This Phase 2 trial of a bivalent AMA1 malaria vaccine found no evidence of vaccine selection or strain-specific efficacy, suggesting that the extreme genetic diversity of AMA1 did not account for failure of the vaccine to provide protection.
Appendix
Available only for authorised users
Literature
1.
2.
Plowe CV, Alonso P, Hoffman SL: The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis. 2009, 200: 1639-1643. 10.1086/646613.CrossRef
3.
Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP: A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002, 185: 820-827. 10.1086/339342.CrossRefPubMed
4.
Matuschewski K, Mueller AK: Vaccines against malaria - an update. FEBS Journal. 2007, 274: 4680-4687. 10.1111/j.1742-4658.2007.05998.x.CrossRefPubMed
5.
Alloueche A, Milligan P, Conway DJ, Minder M, Bojang K, Doherty T, Tornieporth N, Cohen J, Greenwood BM: Protective efficacy of the RTS, S/ASO2 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg. 2003, 68: 97-101.PubMed
6.
Enosse S, Doban C, Quelhas D, Aponte JJ, Lievens M, Leach A, Sacarlal J, Greenwood B, Milman J, Dubovsky F, Cohen J, Thompson R, Ballou WR, Alonso PL, Conway DJ, Sutherland CJ: RTS, S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials. 2006, 1: e5-10.1371/journal.pctr.0010005.PubMedCentralCrossRefPubMed
7.
Kocken CH, van der Wel AM, Dubbeld MA, Narum DL, van de Rijke FM, Van Gemert GJ, van dL X, Bannister LH, Janse C, Waters AP, Thomas AW: Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J Biol Chem. 1998, 273: 15119-15124. 10.1074/jbc.273.24.15119.CrossRefPubMed
8.
Deans JA, Alderson T, Thomas AW, Mitchell GH, Lennox ES, Cohen S: Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol. 1982, 49: 297-309.PubMedCentralPubMed
9.
Thomas AW, Deans JA, Mitchell GH, Alderson T, Cohen S: The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. Mol Biochem Parasitol. 1984, 13: 187-199. 10.1016/0166-6851(84)90112-9.CrossRefPubMed
10.
Kocken CH, Withers-Martinez C, Dubbeld MA, van der WA, Hackett F, Valderrama A, Blackman MJ, Thomas AW: High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen-1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun. 2002, 70: 4471-4476. 10.1128/IAI.70.8.4471-4476.2002.PubMedCentralCrossRefPubMed
11.
Dutta S, Haynes JD, Moch JK, Barbosa A, Lanar DE: Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen-1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci USA. 2003, 100: 12295-12300. 10.1073/pnas.2032858100.PubMedCentralCrossRefPubMed
12.
Thomas AW, Trape JF, Rogier C, Goncalves A, Rosario VE, Narum DL: High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am J Trop Med Hyg. 1994, 51: 730-740.PubMed
13.
Udhayakumar V, Kariuki S, Kolczack M, Girma M, Roberts JM, Oloo AJ, Nahlen BL, Lal AA: Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. Am J Trop Med Hyg. 2001, 65: 100-107.PubMed
14.
Robin Anders, Pauline Crewther, Stirling Edwards, Mai Margetts, Mary Matthew, Bronwyn Pollock, David Pye: Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine. 1998, 16: 240-247. 10.1016/S0264-410X(97)88331-4.CrossRef
15.
Nair M, Hinds MG, Coley AM, Hodder AN, Foley M, Anders RF, Norton RS: Structure of domain III of the blood stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1. J Mol Biol. 2002, 322: 741-753. 10.1016/S0022-2836(02)00806-9.CrossRefPubMed
16.
Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, Escalante AA, Ouattara A, Traoré K, Niangaly A, Djimdé A, Doumbo OK, Plowe CV: Extreme polymorphism in a vaccine antigen and risk of clinical malaria: Implications for vaccine development. Sci Transl Med. 2009, 1: 2ra5-PubMedCentralCrossRefPubMed
17.
Bai T, Becker M, Gupta A, Strike P, Murphy VJ, Anders RF, Batchelor AH: Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci USA. 2005, 102: 12736-12741. 10.1073/pnas.0501808102.PubMedCentralCrossRefPubMed
18.
Cowman AF, Crabb BS: Invasion of red blood cells by malaria parasites. Cell. 2006, 124: 755-766. 10.1016/j.cell.2006.02.006.CrossRefPubMed
19.
Dutta S, Lee SY, Batchelor AH, Lanar DE: Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci USA. 2007, 104: 12488-93. 10.1073/pnas.0701464104.PubMedCentralCrossRefPubMed
20.
Dicko A, Sagara I, Ellis RD, Miura K, Guindo O, Kamate B, Sogoba M, Niambele MB, Sissoko M, Baby M, Dolo A, Mullen GED, Fay MP, Pierce M, Diallo DA, Saul A, Miller LH, Doumbo OK: Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS ONE. 2008, 3: e1563-10.1371/journal.pone.0001563.PubMedCentralCrossRefPubMed
21.
Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, Assadou MH, Guindo O, Kamate B, Baby M, Sissoko M, Malkin ME, Fay MP, Thera MA, Miura K, Dolo A, Diallo DA, Mullen GE, Long CA, Saul A, Doumbo O, Miller LH: Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians. PLoS ONE. 2007, 2: e1045-10.1371/journal.pone.0001045.PubMedCentralCrossRefPubMed
22.
Cortés A, Mellombo M, Mueller I, Benet A, Reeder JC, Anders FA: Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun. 2003, 71: 1416-1426. 10.1128/IAI.71.3.1416-1426.2003.PubMedCentralCrossRefPubMed
23.
Remarque EJ, Faber BW, Kocken CHM, Thomas AW: Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 2007, 24: 74-84. 10.1016/j.pt.2007.12.002.CrossRef
24.
Snow RW, Guerra CA, Noor MA, Myint HY, Hay SI: The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005, 434: 214-217. 10.1038/nature03342.PubMedCentralCrossRefPubMed
25.
Crewther PE, Matthew ML, Flegg RH, Anders RF: Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun. 1996, 64: 3310-3317.PubMedCentralPubMed
26.
Hodder AN, Crewther PE, Anders RF: Specificity of the Protective Antibody Response to apical membrane antigen 1. Infect Immun. 2001, 69: 3286-3294. 10.1128/IAI.69.5.3286-3294.2001.PubMedCentralCrossRefPubMed
27.
Barclay VC, Brian H.K, Chan BHK, Anders RF, Read AF: Mixed allele malaria vaccines: Host protection and within-host selection. Vaccine. 2008, 26: 6099-6107. 10.1016/j.vaccine.2008.09.004.PubMedCentralCrossRefPubMed
28.
Takala S-L, Plowe CV: Genetic diversity and malaria vaccine design, testing, and efficacy: Preventing and overcoming "vaccine resistant malaria. Parasite Immunol. 2009, 31: 560-573. 10.1111/j.1365-3024.2009.01138.x.PubMedCentralCrossRefPubMed
29.
Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, Sissoko MS, Kone M, Diallo AI, Saye R, Guindo MA, Kante O, Niambele MB, Miura K, Mullen GE, Pierce M, Martin LB, Dolo A, Diallo DA, Doumbo OK, Miller LH, Saul A: A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine. 2009, 27: 3090-3098. 10.1016/j.vaccine.2009.03.014.PubMedCentralCrossRefPubMed
30.
Duan J, Mu J, Thera MA, Joy D, Pond SLK, Diemert D, Long C, Zhou H, Miura K, Ouattara A, Dolo A, Doumbo O, Su X, Miller L: Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: Implications for vaccine design. Proc Natl Acad Sci USA. 2008, 105: 7857-7862. 10.1073/pnas.0802328105.PubMedCentralCrossRefPubMed
31.
Tamura K, Dudley J, Nei M, Kumar S: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007, 24: 1596-1599. 10.1093/molbev/msm092.CrossRefPubMed
32.
Rozas J, Sanchez-Delbarrrio JC, Messeguer X, Rozas R: DNASP, DNA polymorphism analyses by a coalescent and other methods. Bioinformatics. 2003, 19: 2496-2497. 10.1093/bioinformatics/btg359.CrossRefPubMed
33.
Falush D, Stephens M, Pritchard JK: Inference of population structure using multilocus genotype data: Linked loci and correlated allele frequencies. Genetics. 2003, 164: 1567-1587.PubMedCentralPubMed
34.
Dicko A, Mantel C, Kouriba B, Sagara I, Thera MA, Doumbia S, Diallo M, Poudiougou B, Diakite : Ogobara Doumbo Ok: Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali. Trop Med Int Health. 2005, 10: 550-556. 10.1111/j.1365-3156.2005.01418.x.CrossRefPubMed
35.
Genton B, Reed ZH: Asexual blood-stage malaria vaccine development: facing the challenges. Curr Opin Infect Dis. 2007, 20: 467-475. 10.1097/QCO.0b013e3282dd7a29.CrossRefPubMed
36.
Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH: Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun. 2002, 70: 6961-6967. 10.1128/IAI.70.12.6961-6967.2002.PubMedCentralCrossRefPubMed
37.
Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW: In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun. 2002, 70: 6948-6960. 10.1128/IAI.70.12.6948-6960.2002.PubMedCentralCrossRefPubMed
38.
Ellis RD, Mullen GE, Pierce M, Martin LB, Miura K, Fay MP, Long CA, Shaffer D, Saul A, Miller LH, Durbin AP: A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine. 2009, 27: 4104-4109. 10.1016/j.vaccine.2009.04.077.PubMedCentralCrossRefPubMed
39.
Sagara I, Ellis RD, Dicko A, Niambele MB, Kamate B, Guindo O, Sissoko MS, Fay MP, Guindo MA, Kante O, Saye R, Miura K, Long C, Mullen GE, Pierce M, Martin LB, Rausch K, Dolo A, Diallo DA, Miller LH, Doumbo OK: A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine. 2009, 27: 7292-7298. 10.1016/j.vaccine.2009.10.087.PubMedCentralCrossRefPubMed
40.
Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, Fay MP, Saul A, Zhu D, Rausch K, Moretz S, Zhou H, Long CA, Miller LH, Treanor J: Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE. 2008, 3: e2940-10.1371/journal.pone.0002940.PubMedCentralCrossRefPubMed
41.
Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, Traore K, Dicko A, Sagara I, Sissoko MS, Baby M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M, Diawara SI, Heppner DG, Stewart VA, Angov E, Bergmann-Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A, Owusu A, Dubois MC, Cohen J, Nixon JN, Gregson A, Takala SL, Lyke KE, Plowe CV: Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS ONE. 2008, 3: e1465-10.1371/journal.pone.0001465.PubMedCentralCrossRefPubMed
42.
Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone KA, Guindo AB, Traore K, Sissoko M, Diallo DA, Issa Diarra, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara A, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois MCW, Ballou R, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, Takala SL, Lyke KE, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV: Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial. PLoS ONE. 2010, 5: e9041-10.1371/journal.pone.0009041.PubMedCentralCrossRefPubMed
Metadata
Title
Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine
Authors
Amed Ouattara
Jianbing Mu
Shannon Takala-Harrison
Renion Saye
Issaka Sagara
Alassane Dicko
Amadou Niangaly
Junhui Duan
Ruth D Ellis
Louis H Miller
Xin-zhuan Su
Christopher V Plowe
Ogobara K Doumbo
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2010
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-9-175

Other articles of this Issue 1/2010

Malaria Journal 1/2010 Go to the issue

Research

Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy

Research

The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator?

Research

Congenital and neonatal malaria in a rural Kenyan district hospital: An eight-year analysis

Research

Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum

Review

Predicting and mapping malaria under climate change scenarios: the potential redistribution of malaria vectors in Africa

Research

Cost effectiveness of OptiMal® rapid diagnostic test for malaria in remote areas of the Amazon Region, Brazil

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits